Pharmacology
Original Paper
Effect of Captopril on Urinary Kallikrein, Blood Pressure and Myocardial Hypertrophy in Diabetic Spontaneously Hypertensive RatsSharma J.N. · Kesavarao U.School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: March 06, 2002
Issue release date: April 2002
Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 0
ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)
For additional information: https://www.karger.com/PHA
Abstract
We investigated the total urinary kallikrein levels, left-ventricular wall thickness and mean arterial blood pressure of nontreated and captopril-treated diabetic and nondiabetic spontaneously hypertensive rats. The mean arterial blood pressure was significantly elevated in diabetic spontaneously hypertensive rats as compared to nondiabetic spontaneously hypertensive rats. Captopril treatment caused a significant reduction in the arterial blood pressure of both nondiabetic and diabetic spontaneously hypertensive rats. The left-ventricular wall thickness was also significantly reduced in diabetic and nondiabetic spontaneously hypertensive treated with captopril as compared to nontreated diabetic and nondiabetic spontaneously hypertensive rats. The total urinary kallikrein levels were significantly raised in captopril-treated diabetic and nondiabetic spontaneously hypertensive rats against the values obtained from nontreated diabetic and nondiabetic spontaneously hypertensive rats. These results indicate that blood pressure reduction and left ventricular wall regression with captopril treatment might be due to enhanced renal kallikrein formation. The significance of these findings is discussed.
© 2002 S. Karger AG, Basel
Related Articles:
References
-
Margolius HS, Geller R, Pisano JJ, Sjoerdsma A: Altered urinary kallikrein excretion in human hypertension. Lancet 1971;ii:1062–1065.
-
Mohsin SSJ, Majima M, Katori M, Sharma JN: Important suppressive roles of the kallikrein-kinin system during the development stage of hypertension in spontaneously hypertensive rats. Asia Pacific J Pharmacol 1992;7:73–82.
External Resources
- Sharma JN: Interrelationship between the kallikrein-kinin system and hypertension. Gen Pharmacol 1988;19:177–187.
- Nustad K: Relationship between kidney and urinary kininogenases. Br J Pharmacol 1970;39:73–86.
- Sharma JN, Uma K, Noor AR, Rahaman ARA: Blood pressure regulation by the kallikrein-kinin system. Gen Pharmacol 1996;27:55–63.
- Jaffa AA, Miller D, Bailey GS, Chao J, Margolius HS, Mayfield RK: Abnormal regulation of renal kallikrein in experimental diabetes. J Clin Invest 1987;80:1651–1659.
- Sharma JN: Does kinin mediate the hypotensive action of angiotensin converting enzyme (ACE) inhibitors? Gen Pharmacol 1990;21:451–457.
- Sharma JN, Amrah SS, Noor AR: Suppression of hypotensive responses of captopril and enalapril by kallikrein inhibitor aprotinin in spontaneously hypertensive rats. Pharmacology 1995;50:363–369.
- Factor SM, Bhan R, Minase T, Wolinsky H, Sonnenblick EH: Hypertensive diabetic cardiomyopathy in the rat: an experimental model of human disease. Am J Pathol 1981;102:219–228.
-
Hayashi M, Senba S, Saito I, Kitajima W, Saruta T: Changes in blood pressure, urinary kallikrein, and prostaglandin E2 in rats with streptozotocin-induced diabetes. Arch Pharmacol 1983;322:329–394.
- Anversa P, Olivetti G, Melissari M, Loud AV: Morphometric study of myocardial hypertrophy induced by abdominal aortic stenosis. Lab Invest 1979;40:341–348.
-
Amundsen E, Putter J, Friberger P, Knos M, Larsbraten M, Glaeseaon G: Method for the determination of glandular kallikrein by means of chromogenic tripeptide substrate. Adv. Exp Med Biol 1979;120A:83–95.
-
Kawashima H, Igarashi T, Nakajima Y, Akiyama Y, Usuki K, Ohtake S: Chronic hypertension induced by streptozotocin in rats. Arch Pharmacol 1979;305:123–126.
-
Pellufo V, Costa MA, Prendes MGM, Catanzaro OL: Renal alteration and development of hypertension in diabetic rats. Agents Actions 1992;38(suppl 2):50–57.
- Somani P, Singh HP, Saini PK, Rabinovich A: Streptozotocin induced diabetes in the spontaneously hypertensive rats. Metabolism 1979;28:1075–1077.
-
Silberbauer K, Stanek B, Temple H: Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition. Br J Clin Pharmacol 1982;14:87S–93S.
External Resources
- Sharma JN, Fernandez PG, Kim BK, Idikio H, Triggle CR: Cardiac regression and blood pressure control in the Dahl rat treated with enalapril (MK421, an angiotensin converting enzyme inhibitor) and hydrochlorothiazide. J Hypertens 1983;1:251–256.
-
Sharma JN, Stewart JM, Mohsin SSJ, Katori M, Vavrek R: Influence of a kinin antagonist on acute hypotension responses induced by bradykinin and captopril in spontaneously hypertensive rats. Agents Actions 1992;38(suppl 3):258–269.
- Trippodo NC, Frohlich ED: The genetically hypertensive rat as a model of human essential hypertension. Circ Res 1981;48:309–319.
- Sharma JN, Uma K, Yusof APM: Left ventricular hypertrophy and its relation to the cardiac kinin-forming system in hypertensive and diabetic rats. Int J Cardiol 1998;63:229–235.
-
Linz W, Wiemer G, Scholken BA: Bradykinin prevents left ventricular hypertrophy in rats. J Hypertens 1993;11(suppl 5):S96–S97.
- Ader JL, Pollack DM, Butterfield MI, Arendshort WJ: Abnormalities in kallikrein excretion in spontaneously hypertensive rats. Am J Physiol 1985;248:F396–F403.
- Margolius HS, Geller R, De Jong W, Pisano JJ: Altered urinary kallikrein excretion in rats with hypertension. Circ Res 1972;30:358–362.
- Majima M, Katori M, Hanazuka M, Mizogami S, Nakano T, Akao Y, Mikami R, Uryu H, Okamura R, Mohsin SSJ, Oh-ishi: Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system. Hypertension 1991;17:806–813.
-
Chao J, Chao L: Kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Gene Ther Molec Biol 1998;1:301–308.
- Overlack A, Stumpe KO, Kollock R, Ressel C, Krueck F: Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Hypertension 1981;3:I18–I21.
- Sen S, Tarazi RC, Bumpus FM: Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res 1977;11:427–433.
- Dahlof B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients: A metanalysis of 109 treated studies. Am J Hypertens 1992;5:95–110.
Article / Publication Details
Published online: March 06, 2002
Issue release date: April 2002
Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 0
ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)
For additional information: https://www.karger.com/PHA
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
